Conference Call with Vimta Labs Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Vimta Labs announced Q1FY25 results: Total Income for Q1FY25 was at Rs 824 million EBITDA for Q1FY25 was Rs 252 million; EBITDA margin was at 30.6% PBT for Q1FY25 was at Rs 165 million Q1FY25 PAT was at Rs 123 million; PAT margin was at 14.9% Basic EPS in Q1FY25 was Rs 5.5 Total Debt as of June 30, 2024 stood at Rs 130 million Cash and Cash equivalents were at Rs 324 million as of June 30, 2024 Q1FY25 Capex spent was at Rs 164 million Debt to Equity ratio was 0.04x Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report stable business momentum with encouraging QoQ sales growth and stable EBITDA margins. Despite a challenging internal and external environment, we achieved a QoQ growth in sales, driven by Pharmaceutical services which demonstrated sustained growth, albeit slightly tempered by the other services. Looking ahead, we are pleased to share that our new Life Sciences facility expansion will become operational in Q2 of this financial year. This facility is expected to play a significant role in driving our growth in the coming quarters. We remain optimistic about the future and are dedicated to fostering sustainable growth." Result PDF